NCT00077532View on ClinicalTrials.gov

Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma

PHASE2CompletedINTERVENTIONAL

Enrollment

179

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

January 31, 2007

Study Completion Date

February 29, 2008

Conditions

Melanoma (Skin)

Interventions

BIOLOGICAL

gp100 antigen

BIOLOGICAL

incomplete Freund's adjuvant

BIOLOGICAL

ipilimumab

Trial Locations (1)

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

National Institutes of Health Clinical Center (CC)

NIH

NCT00077532 - Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma | Biotech Hunter | Biotech Hunter